ProPhase Labs, Inc. Stock: price and insider trades · United States

ProPhase Labs, Inc. (NASDAQ: PRPH) is a US-listed micro-cap company traded on the Nasdaq Capital Market in the United States. For French-, Belgian- and Swiss-based investors, it is best viewed as a small but highly event-driven healthcare name undergoing an ongoing strategic reset, with valuation drivers tied to clinical milestones, intellectual property, financing decisions and corporate portfolio changes. The company is based in Uniondale, New York, and presents itself as a next-generation biotech, genomics and consumer products business. ProPhase Labs was founded in 1989 and has evolved over time from a more traditional consumer-health model toward a more technology-oriented platform spanning diagnostics, genomics and health-related consumer offerings.

The business today is centered on several operating pillars. First, ProPhase is building out its diagnostics and genomics footprint through Nebula Genomics and its BE-Smart™ esophageal disease risk-assessment test. The latter is intended to help assess risk for esophageal adenocarcinoma and related disease pathways, and management has highlighted the asset as a key commercialization opportunity. Second, the company retains a consumer health and wellness component, historically associated with supplements and branded consumer products. Third, recent disclosures show a growing emphasis on non-core asset monetization and liquidity optimization, including the Crown Medical Collections initiative, which was highlighted in 2026 as a potential source of near-term cash flow.